Intrexon Corp.(NYSE:XON) has recently started working along with Merck Serono. This collaboration is going to boost up Intrexon Corp.(NYSE:XON)’s market and its R&D partner ZIOPHARM Oncology Inc. (NASDAQ:ZIOP)’s immuno-oncology programs. ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) and Intrexon Corp.(NYSE:XON)’s (NYSE:XON) programs of oncology are foreseeing tremendous growth from Intrexon Corp.(NYSE:XON)’s upcoming partnership with Merck Serono, which is the world famous biopharmaceutical unit of Merck KGaA (OCTMKTS:MKGAY).
This created hustle in the stocks since the stocks have raised up in yesterday’s sessions of these three companies. Intrexon Corp.(NYSE:XON)has gone upto 7.67%, Merck KGaA boosting to 2.17%, and ZIOPHARM Oncology Inc. (NASDAQ:ZIOP)going up 1.44%. The alliance of Intrexon Corp.(NYSE:XON)and Merck Serono is going to emphasize completely on chimeric antigen receptor T-cell (CAR-T) products. Intrexon Corp.(NYSE:XON)and Merck will split the alliance expenses equally including beforehand and afterwards payments.
CAR-T shows cell based transfer, now under scientific procedures it is being shown how it can help in treating cancer. The T cells are kind of white blood cells that help in developing immunity with cell mediation. These are detached from a patient and scientifically handled in a way that they express receptors to target a great number of types of cancer. These are then injected back into the patients’ body in order to fight cancer cells.
Jonathan Lewis, chief executive of ZIOPHARM Oncology Inc. (NASDAQ:ZIOP), expressed the great advantage of CAR-T procedure which enable a healthy response from the immune system thus treating lot of cancer ailments. Mr. Lewis also believes that the partnership with Intrexon Corp. (NYSE:XON) and Merck Serono is going to bring world class solutions and extraordinary changes through CAR-T treatments. Two self-created CAR-T will be researched and tested.
This investment is going to be funded by Merck Serono;ZIOPHARM Oncology Inc. (NASDAQ:ZIOP)and Intrexon Corp. (NYSE:XON)will be giving additional expenses for R&D funds. The clinical development and research will be funded by Merck Serono till the procedure reaches the stage of investigational new drug. ZIOPHARM Oncology Inc. (NASDAQ:ZIOP)and Intrexon Corp. (NYSE:XON)will be doing independent working on CAR-T mechanisms.
Merck can intervene at any time when the clinical development is in process. ZIOPHARM Oncology Inc. (NASDAQ:ZIOP)in alliance with Intrexon Corp. (NYSE:XON)is going to continue its analysis and research in the treatment of cancer on the basis of cell based treatment. ZIOPHARM Oncology Inc. (NASDAQ:ZIOP)and its partnership with Merck will help Intrexon Corp. (NYSE:XON)in achieving high milestones in cancer treatment.
Gregory Frost, senior vice president and head of Intrexon’s Health Sector believes that this alliance with ZIOPHARM and Merck will be helpful in developing new prospects in synthetic immune oncology and new medicines in market.
